Form 4: Omnicell EVP & CFO Etta Nchacha Reports Stock Transactions

Etta Nchacha, EVP & CFO of Omnicell, reports the acquisition and disposal of common stock related to performance-based restricted stock units.

Summary

• On March 8, 2025, Etta Nchacha, EVP & CFO of Omnicell, reported transactions involving Omnicell's common stock.
• Nchacha acquired 66,633 shares of common stock at $0 related to performance-based restricted stock units.
• These units were granted on February 27, 2024, and were contingent on Omnicell meeting certain stock performance objectives compared to the S&P 1000 Healthcare Index.
• The Compensation Committee determined that the performance criteria were met at 176% of target, resulting in the vesting of these units.
• 25% of the units vested immediately on the determination date, and the remaining units will vest in equal quarterly increments over three years.
• Nchacha also disposed of 5,368 shares at $36.99 to cover taxes due in connection with the vesting of the restricted stock units.
• Following these transactions, Nchacha beneficially owns 132,023 shares of Omnicell common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The vesting of performance-based restricted stock units suggests the company is meeting its performance goals. The tax-related disposal is a normal part of equity compensation.

Positives

• The vesting of performance-based restricted stock units indicates that Omnicell met its stock performance objectives compared to the S&P 1000 Healthcare Index.
• The performance criteria were met at 176% of target, suggesting strong performance.

Negatives

• The disposal of 5,368 shares to cover taxes indicates a taxable event for the reporting person.

Future Outlook

The remaining performance-based restricted stock units will vest in equal quarterly increments once every three months over a three-year period (on each May 15, August 15, November 15, and February 15, respectively).

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It reflects the alignment of executive incentives with company performance.

Comparison to Industry Standards

• Performance-based equity compensation is a common practice among publicly traded companies, particularly in the healthcare sector.
• The use of the S&P 1000 Healthcare Index as a benchmark is a reasonable approach to measuring Omnicell's relative performance.
• Vesting schedules and performance targets vary across companies, but the three-year vesting period with quarterly increments is fairly standard.

Stakeholder Impact

• Shareholders may view the vesting of performance-based restricted stock units positively, as it indicates that the company is achieving its performance goals.
• Employees who hold similar equity grants may also be encouraged by the vesting.

Key Dates